REDUCTION OF ASTHMA EXACERBATIONS FOLLOWING INITIATION OF SINGLE-INHALER TRIPLE THERAPY WITH FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL IN US CLINICAL CARE

被引：0
|
作者：
Bogart, Michael
Germain, Guillaume
Laliberte, Francois
Mahendran, Malena
Duh, Mei S.
Dirocco, Kristi
Noorduyn, Stephen G.
Paczkowski, Rosirene
Balkissoon, Ronald C.
机构：
来源：
CHEST | 2023年 / 164卷 / 04期
关键词：
D O I：
10.1016/j.chest.2023.07.4209
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：6527A / 6528A
页数：2
相关论文
共 50 条
  • [41] Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study
    Pavord, Ian
    Peachey, Guy
    Kerstjens, Huib
    Kerwin, Edward
    Nathan, Robert
    Hanania, Nicola A.
    Pascoe, Steven
    Fowler, Andrew
    Bailes, Zelie
    Edwards, Dawn
    Sule, Neal
    Barnes, Neil
    Boulet, Louis-Philippe
    Tabberer, Maggie
    Lee, Laurie A.
    ALLERGY AND ASTHMA PROCEEDINGS, 2020, 41 (06) : 459 - 460
  • [42] Captain Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma
    Lee, L.
    Boulet, L.
    Fowler, A.
    Tabberer, M.
    Bailes, Z.
    Pascoe, S.
    Kerwin, E. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [43] EFFECT OF AGE ON EFFICACY AND SAFETY OF ONCE-DAILY SINGLE-INHALER TRIPLE THERAPY FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL IN PATIENTS WITH COPD: A POST-HOC ANALYSIS OF THE IMPACT TRIAL
    Hanania, Nicola
    Mannino, David
    Criner, Gerard
    Dransfield, Mark
    Han, Meilan
    Jones, Christine Elaine
    Kilbride, Sally
    Lomas, David
    Martinez, Fernando
    Singh, Dave
    Wise, Robert
    Halpin, David
    Soule, Tedi
    Lima, Robson
    Lipson, David
    CHEST, 2019, 156 (04) : 1750A - 1754A
  • [44] Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial
    Panettieri, Reynold A., Jr.
    Camargo, Carlos A., Jr.
    Cheema, Tariq
    Bayadi, Sherif G. El
    Fiel, Stanley
    Vila, Tania M.
    Jain, Renu G.
    Midwinter, Dawn
    Thomashow, Byron
    Ludwig-Sengpiel, Andrea
    Lipson, David A.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 2043 - 2052
  • [45] COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA
    Hanania, Nicola A.
    Bunner, Scott H.
    Bengtson, Lindsay G. S.
    Ismaila, Afisi S.
    Bogart, Michael
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2023, 18 : 407 - 418
  • [46] Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes
    David Mannino
    Kristi DiRocco
    Guillaume Germain
    François Laliberté
    Stephen G. Noorduyn
    Ana Urosevic
    Rosirene Paczkowski
    Advances in Therapy, 2024, 41 (12) : 4557 - 4580
  • [47] Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label Study
    Hozawa, Soichiro
    Ohbayashi, Hiroyuki
    Tsuchiya, Michiko
    Hara, Yu
    Lee, Laurie A.
    Nakayama, Takashi
    Tamaoki, Jun
    Fowler, Andrew
    Nishi, Takanobu
    JOURNAL OF ASTHMA AND ALLERGY, 2021, 14 : 809 - 819
  • [48] Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study (vol 24, 229, 2023)
    Ismaila, Afisi S.
    Rothnie, Kieran J.
    Wood, Robert P.
    Banks, Victoria L.
    Camidge, Lucinda J.
    Czira, Alexandrosz
    Compton, Chris
    Sharma, Raj
    Millard, Shannon N.
    Massey, Olivia
    Halpin, David M. G.
    RESPIRATORY RESEARCH, 2024, 25 (01)
  • [49] CAPTAIN STUDY: TREATMENT OUTCOMES FROM FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL ACCORDING TO HISTORY OF SEVERE ASTHMA EXACERBATIONS
    Oppenheimer, J.
    Brusselle, G.
    Busse, W.
    Fowler, A.
    Jain, N.
    Mannino, D.
    Pavord, I.
    Win, P.
    Zarankaite, A.
    Kerwin, E.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S26 - S27
  • [50] Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States
    Bogart, Michael
    Bengtson, Lindsay G. S.
    Johnson, Mary G.
    Bunner, Scott H.
    Gronroos, Noelle N.
    Dirocco, Kristi K.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2024, 19 : 97 - 110
12345